Skip to content
Part 3-Gene Therapy: An Industry Perspective episode artwork

Nov 6, 2020 23 min

Part 3-Gene Therapy: An Industry Perspective

from RARECast

Though there are only a handful of gene therapies on the market today, there is a robust and growing pipeline of these transformative medicines advancing toward market. In this third part of our gene therapy series we spoke to Janet Lambert, CEO of the Alliance for Regenerative Medicine, about the state of the gene therapy industry, the challenges developers face in advancing therapies to the market, and emerging pricing approaches to make them accessible to the patients who need them. This series is made possible through support from BioMarin, Pfizer, Retrophin, Novartis Gene Therapies (formerly AveXis), UCB Inc., Genentech, Ultragenyx, Novartis, RegenxBIO, and Sangamo Therapeutics.

Episode details come from the podcast's RSS feed.

Embed this episode

Janet Lambert, CEO of the Alliance for Regenerative Medicine, discusses the state of the gene therapy industry, the challenges developers face in advancing therapies to the market, and emerging pricing approaches to make them accessible to the patients who need them.

Ready to play

Part 3-Gene Therapy: An Industry Perspective

0:00 23:03

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 23 minutes long.

When was this RARECast episode published?

This episode was published on November 6, 2020.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.